PMA patent complaint v. Korea
PMA President Mossinghoff is asking the Commerce Department via a March 10 letter "to send an appropriate signal to Korea" for what the association called deviations from a bilateral U.S.-South Korean agreement. "For the past year," the association maintained, "the Korean government has sought to renegotiate the agreement it signed in order to inhibit the sale of U.S. patented products in that country." PMA charged that Korea is not protecting drug product or process patents and is not enforcing its pre-agreement patent laws.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.